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from outcome analysis. Of the remaining 28 patients, ﬁve
HSCT recipients (4 allo and 1 auto) have died (18%). All pa-
tients who died were in the lower respiratory tract infection
group and their death was directly attributed to pulmonary
complications as a result of respiratory virus infections. Two
patients died from adenovirus pneumonitis and ARDS. Two
patients died from severe parainﬂuenza infection with
deterioration of symptoms and respiratory failure despite
treatment with ribavarin and the last patient had ARDS from
RSV infection. No chronic pulmonary complication or allo-
immune lung syndrome was observed among the remaining
23 survivors with a median follow-up time of 3.8 years (8
months-10.3 years).
This study supports the signiﬁcant TRM from respiratory
virus infection diagnosed within the ﬁrst 100 days post HSCT
particularly in patients presented with lower respiratory
tract infection. Higher mortality was observed among allo
recipients. Every effort should be made to prevent respira-
tory virus infections early post HSCT.295
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Introduction: Falls are a common cause of morbidity and
mortality among hospitalized patients in the United States.
Patients with cancer are vulnerable to falls with injury as a
result of complex medical regimens, impaired performance
status, and chemotherapy toxicities such as neuropathy.
Predictors of falls in the general oncology population
include abnormal gait, presence of metastasis, antide-
pressant and antipsychotic medication use, and blood
product use. Risk factors for falls in the hematopoietic
stem cell transplant (HSCT) population are not as well
understood.
Methods: We performed a retrospective review of patients
admitted to Dana-Farber/Brigham and Women’s Cancer
Center from 01/2011 to 12/2012, who had a fall during their
admission to a HSCT service. Patients were classiﬁed as either
fall or fall with injury (FWI). Our primary objective was to
describe characteristics of hospitalized HSCT patients who
experience a FWI, including medications administered in the
24 hours prior to the fall.
Results: There were 91 falls identiﬁed in 81 patients. One
patient was excluded from the analysis due to incomplete
electronic medical records. Nine patients had more than
one fall. Thirty-two falls resulted in FWI. Fifty-seven falls
(62.6%) occurred during an index admission for HSCT. This
represents 5.48% of our index admissions. Patients had a
history of HSCT or were undergoing myeloablative HSCT
(n¼25), reduced intensity conditioning HSCT (n¼19) or
autologous HSCT (n¼36). Patient and transplant character-
istics were compared between patients who had falls
without injury and patients who had FWI. There was no
signiﬁcant difference in age (p¼0.99), gender (p¼0.65),
cancer diagnosis (p¼0.84), hospital admission team
(p¼0.99), admission type (p¼0.14) or transplant type
(p¼0.80) between patients with falls and FWI. Inmultivariate analysis, benzodiazepine use (p¼0.016) and
Morse Fall score  45 (p¼0.031) were associated with
increased risk of FWI, whereas diuretic use (p¼0.029),
presence of heart disease (p¼0.023) and prior fall (p¼0.015)
were associated with decreased risk of FWI.
Conclusions: Falls are common in patients hospitalized for
HSCT. Benzodiazepine use and high Morse Fall score predict
for an increased risk of injury after a fall event. Adequate
assessment and management of these modiﬁable fall risk
factors, including decreasing our benzodiazepine use and
early identiﬁcation of at risk patients may help prevent FWI
in our HSCT population.296
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Respiratory syncytial virus (RSV) in the immunocompromised
adult can lead to signiﬁcant morbidity and mortality. Most
immunocompromised patients with RSV pneumonia present
to a health care facility with an upper respiratory tract infec-
tionw1 week prior to the onset of pneumonia. Overall, 40%e
50% of RSV upper respiratory tract infections (URTI) in HCT
recipients will progress to pneumonia. RSV pneumonia in HCT
recipients is associated with fatality rates as high as 70e80%.
Treatment of RSV pneumonia is primarily supportive. The role
of speciﬁc antiviral therapy remains uncertain. We retro-
spectively reviewed RSV-infected patients with upper or
lower respiratory tract infection (LRTI) diagnosed by antigen
testing, polymerase chain reaction and/or culture from
January 2007 through March 2013. In general, clinically stable
URTI patients with an absolute lymphocyte count (ALC)> 300
received only supportive care. Patients presenting with URTI
and lymphopenia (ALC  300) were preferentially treated
with a course of inhaled ribavirin (IR) alone. Those presenting
with LRTI were preferentially treated with IR in combination
with the RSV-speciﬁc humanized monoclonal antibody, Pal-
ivizumab. We identiﬁed 60 consecutive patients who were
diagnosed with RSV (median age 52 [21 - 72]) - 35 had URTI
and 25 had LRTI. Forty-one (71%) of the patients had received
an allogeneic transplant, seven (12%) were post autologous
transplant, while 10 (17%) were receiving treatment for acute
leukemia. Of the allogeneic transplant patients, 31 (51.6 %)
were receiving immunosuppressants and 24 (40%) were being
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median (range) ANC and ALC at the time of RSV diagnosis was
1.6 (0 - 11) and 0.8 (0 - 7.3), respectively. Among the 35 pa-
tients with URTI, 12 received IR while 23 did not. None of the
12 patients treatedwith IR progressed to LRTI. In contrast, 6 of
the 23 untreated patients (24%) with URTI progressed to LRTI.
Of the 31 patients with LRTI (25 initially diagnosed with LRTI
and 6 patients who progressed from URTI to LRTI), there were
four deaths occurring within 60 days of RSV diagnosis (two
deaths directly from RSV, one from disease relapse, and one
from GVHD). In patients with LRTI (25 patients with LRTI at
diagnosis plus 6 patients who progressed from URTI to LRTI),
RSV-related mortality was (6.4%). On univariate analysis, only
the presence of GVHD signiﬁcantly predicted the develop-
ment of LRTI in patients with URTI (P ¼ .028); however, the
use of inhaled ribavirin had a protective effect that was
marginally signiﬁcant (P¼ .074). Early use of IR in high-risk
transplant and leukemia patients can both reduce the pro-
gression fromURTI to LRTI and improve the historically dismal
outcomes of patients with RSV pneumonia.297
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Clinical Question (in PICO format)
Background / Purpose of BESt Development
Hemopoietic stem cell transplant can have profound and
lasting adverse effects on an individual’s physical and psy-
chological well-being (Wolin 2010 [1a], Tsimicalis 2005 [1a],
Baumann 2011 [2b], Jarden 2009 [2b]). The HSCT treatment
results in a decline in physical function functioning related to
loss of muscle mass and muscle strength andmuscle atrophy
is associated with several transplant related problems,
including immunosuppressive therapy, bed rest, and drug
toxicities (Wolin 2010 [1a], Knols 2005 [1a], Wiskemann 2008
[1b], Baumann 2011 [2b]). The experience of the isolated
environment and the stress of a life threatening illness,
resulting in fatigue, anxiety, depression, and fear, may also
contribute to negative effects on physical function and QoL
(Tsimicalis 2005 [1a]).
Chemotherapy results in anemia, which can affect cardiore-
spiratory ﬁtness and cause skeletal muscle atrophy and
weakness. Chemotherapy toxicities can impede adequate
nutrition needed to maintain muscle mass. Radiation therapy
can lead to lung ﬁbrosis, resulting in decreased pulmonary
function. Cranial radiation in childhood has been strongly
linked to physical inactivity during adulthood (Wolin 2010
[1a]). Individuals being treated for pediatric cancers, in
particular, tend to experience adverse effects of treatment
including impaired growth, decreased neurological and/or
cardiac function, endocrine complications, osteoporosis and
obesity (Wolin 2010 [1a]). All of these side effects can lead to a
decline in physical functioning and contribute to experiences
of fatigue, anxiety, and depression (Wolin 2010 [1a]).P: Among school aged children and adolescents receiving
hemopoietic stem cell transplant (HSCT)
I: does physical therapy (PT) intervention (active participation
in mobility, endurance, strength exercise)
C: compared to no intervention
O: improve the patient’s quality of life (QoL)?In addition to the symptoms and side effects, the treatment
requires prolonged isolation, which can also impede func-
tional activity and impair psychological well-being (Trem-
olada 2009 [1b]). Activity restrictions and limited exercise
options hinder the individual’s ability to sustain physical
function throughout this process. Mentally, the challenges
pediatric patients experience while undergoing HSCT may
have a long lasting impact on QoL (Tremolada 2009 [1b]).
Because survival rates have increased, the need to address
these quality of life issues and the impact of functional
impairment has grown signiﬁcantly. It is important to
consider not only immediate survival, but also long term
recovery of this patient population. The purpose of devel-
oping this BESt was to identify interventions that can
improve function and positively impact outcomes improving
HSCT pediatric patients’ QoL.298
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Backgrounds: Both tacrolimus and glycopeptide antibiotics
are nephrotoxic, and are frequently co-administered after
hematopoietic stem cell transplantation (HSCT). The aim of
this study is to evaluate the nephrotoxicity of co-adminis-
tration of tacrolimus and glycopeptide antibiotic, teicoplanin,
in HSCT recipients.
Patients and Methods: Sixty-seven patients who received
intravenous tacrolimus and teicoplanin concomitantly for
more than four days after allogeneic HSCT were retrospec-
tively examined. Therapeutic drug monitoring (TDM) was
performed in all patients both for tacrolimus and teicoplanin.
Results: The median duration of the co-administration of
tacrolimus and teicoplanin was 11 days (range: 4-40). The
mean serum creatinine (sCr) level tended to be elevated after
the co-administration of tacrolimus and teicoplanin (from
0.690.26 to 0.750.30 mg/dL; P¼ 0.08); however, a two-
fold or greater increase of sCr was observed only in 2 (3.0%)
patients. Increased sCr was tolerable and reversible.
Conclusion: These results suggest that the nephrotoxicity of
the co-administration of tacrolimus and teicoplanin is min-
imal after allogeneic HSCT if the TDM of each drug is properly
applied.299
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Japanese encephalitis (JE) virus is one of the most wide-
spread causes of viral encephalitis in Asia and western pa-
ciﬁc. JE causes long-term neurological morbidities and
mortality. National implementation of JE vaccine effectively
reduces incidences of JE in Asian countries. A live-attenuated
